The G protein estrogen receptor (GPER) is regulated by endothelin-1 mediated signaling in cancer cells

Cellular Signalling

Volumn 28, Issue 2, 2016, Pages 61-71

  Bartella, Viviana ^a   De Francesco, Ernestina Marianna ^a   Perri, Maria Grazia ^a   Curcio, Rosita ^a   Dolce, Vincenza ^a   Maggiolini, Marcello ^a   Vivacqua, Adele ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Cancer cells; Endothelin 1; GPER; Migration; Signal transduction

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR A; ENDOTHELIN RECEPTOR B; G PROTEIN COUPLED RECEPTOR; PROTEIN C FOS; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR; GPER PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; WESTERN BLOTTING; ANGIOGENESIS; CELL CULTURE; CELL MOTION; GENETICS; HEP-G2 CELL LINE; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIN-1; HEP G2 CELLS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84947928160     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2015.11.010     Document Type: Article

References (40)

1. Barton M., Yanagisawa M. Can. J. Physiol. Pharmacol. 2008, 86:485-498.
2. Bagnato A., Spinella F., Rosano L. Can. J. Physiol. Pharmacol. 2008, 86:473-484.
3. Rosanò L., Spinella F., Bagnato A. Nat. Rev. Cancer 2013, 13:637-651.
4. Grimshaw M.J. Cancer Lett. 2005, 222:129-138.
5. Wulfing P., Kersting C., Tio J., Fischer R.J., Wulfing C., et al. Clin. Cancer Res. 2004, 10:2393-2400.
6. Lee M.Y., Leung S.W., Vanhoutte P.M., Man R.Y. Eur. J. Pharmacol. 2004, 503:165-172.
7. Prossnitz E.R., Barton M. Nat. Rev. Endocrinol. 2011, 7:715-726.
8. Tsang S.Y., Yao X., Essin K., Wong C.M., Chan F.L., et al. Stroke 2004, 35:1709-1714.
9. Meyer M.R., Field A.S., Kanagy N.L., Barton M., Prossnitz E.R. Life Sci. 2012, 91:623-627.
10. Lappano R., Pisano A., Maggiolini M. Front. Endocrinol. 2014, 5:66.
11. Wang C., Lv X., He C., Hua G., Tsai M.Y., et al. Cell Death Dis. 2013, 4.
12. Wei W., Chen Z.J., Zhang K.S., Yang X.L., Wu Y.M., et al. Cell Death Dis. 2014, 5.
13. Arias-Pulido H., Royce M., Gong Y., Joste N., Lomo L., et al. Breast Cancer Res. Treat. 2010, 123:51-58.
14. Ignatov T., Modl S., Thulig M., Weissenborn C., Treeck O., et al. J. Ovarian Res. 2013, 6:51.
15. He Y.Y., Cai B., Yang Y.X., Liu X.L., Wan X.P. Cancer Sci. 2009, 100:1051-1061.
16. Smith H.O., Arias-Pulido H., Kuo D.Y., Howard T., Qualls C.R., et al. Gynecol. Oncol. 2009, 114:465-471.
17. Smith H.O., Leslie K.K., Singh M., Qualls C.R., Revankar C.M., et al. Am. J. Obstet. Gynecol. 2007, 196:386.
18. Filardo E.J., Graeber C.T., Quinn J.A., et al. Clin. Cancer Res. 2006, 12:6359-6366.
19. Ignatov A., Ignatov T., Weissenborn C., Eggemann H., Bischoff J., et al. Breast Cancer Res. Treat. 2011, 128:457-466.
20. Sjöström M., Hartman L., Grabau D., Fornander T., Malmström P., et al. Breast Cancer Res. Treat. 2014, 145:61-71.
21. Bartella V., De Marco P., Malaguarnera R., Belfiore A., Maggiolini M. Cell. Signal. 2012, 24:1515-1521.
22. De Marco P., Bartella V., Vivacqua A., Lappano R., Santolla M.F., et al. Oncogene 2013, 32:678-688.
23. De Marco P., Romeo E., Vivacqua A., Malaguarnera R., Abonante S., et al. Endocr. Relat. Cancer 2014, 21:739-753.
24. Recchia A.G., De Francesco E.M., Vivacqua A., Sisci D., Panno M.L., et al. J. Biol. Chem. 2011, 286:10773-10782.
25. De Francesco E.M., Lappano R., Santolla M.F., Marsico S., Caruso A., et al. Breast Cancer Res. 2013, 15:64.
26. De Francesco E.M., Pellegrino M., Santolla M.F., Lappano R., Ricchio E., et al. Cancer Res. 2014, 74:4053-4064.
27. Lappano R., Maggiolini M. Nat. Rev. Drug Discov. 2011, 10:47-60.
28. Healy S., Khan P., Davie J.R. Pharm. Ther. Jan. 2013, 137:64-77.
29. Rauh A., Windischhofer W., Kovacevic A., DeVaney T., Huber E., et al. Br. J. Pharmacol. 2008, 154:13-24.
30. Staton C.A., Reed M.W., Brown N.J. Int. J. Exp. Pathol. 2009, 90:195-221.
31. Bouallegue A., Simo Cheyou E.R., Anand-Srivastava M.B., Srivastava A.K. Cell Calcium 2013, 54:428-435.
32. Recchia A.G., Filice E., Pellegrino D., Dobrina A., Cerra M.C., et al. J. Mol. Cell. Cardiol. 2009, 46:352-359.
33. Chu C.Y., Chang C.C., Prakash E., Kuo M.L. J. Biomed. Sci. 2008, 15:675-685.
34. Yoon Y.J., Kim D.K., MYoon C., Park J., Kim Y.K., et al. PLoS One 2014, 9.
35. Wulfing P., Diallo R., Kersting C., Wulfing C., Poremba C., et al. Oncol. Rep. 2004, 4:791-796.
36. Albini A., Tosetti F., Li V.W., Noonan D.M., Li W.W. Nat. Rev. Clin. Oncol. 2012, 9:498-509.
37. Ferrara N. Endocr. Rev. 2004, 25:581-611.
38. Smith H.O., Stephens N.D., Qualls C.R., Fligelman T., Wang T., et al. Mol. Oncol. 2013, 7:41-54.
39. Shankar A., Loizidou M., Aliev G., Fredericks S., Holt D., et al. Br. J. Surg. 1998, 85:502-506.
40. Wang R., Dashwood R.H. Pharmacol. Res. 2011, 63:519-524.